Завершено
Фаза II
Россия
KRP-104; Placebo · ActivX Biosciences, Inc.
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Asses the Safety and Efficacy of Once-Daily KRP-104 in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Alone.